Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

Adults with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) have a poor prognosis, especially if disease burden is high. This post hoc analysis of the phase 3 INO-VATE trial examined the efficacy and safety of inotuzumab ozogamicin (InO) vs. standard of care chemotherapy (SC) among R/R AL...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: DeAngelo, Daniel J., Advani, Anjali S., Marks, David I., Stelljes, Matthias, Liedtke, Michaela, Stock, Wendy, Gökbuget, Nicola, Jabbour, Elias, Merchant, Akil, Wang, Tao, Vandendries, Erik, Neuhof, Alexander, Kantarjian, Hagop, O’Brien, Susan
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7414105/
https://ncbi.nlm.nih.gov/pubmed/32769965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-00345-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados